Abstract
Therapeutic options for the treatment of patent ductus arteriosus (PDA) continue to evolve. Gross and Hubbard reported the first surgical interruption in 1939.1 Transcatheter occlusion was achieved by Portsmann et al in 1971,2 and indomethacin therapy for premature newborns was described in 1976.3 Although preliminary results have been reported for several transcatheter PDA devices, none currently have Food and Drug Administration approval. Transcatheter coils are being placed in many institutions,4 and some patients are awaiting the availability of transcatheter devices. In an effort to reduce surgical trauma, advanced endoscopic imaging technology has been adapted for use in pediatric cardiothoracic surgery, enabling an interruption of the PDA with a minimally invasive transthoracic technique.5

This publication has 0 references indexed in Scilit: